This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Express Scripts, others shouldn't be granted injunction, US FTC tells appeals court

( May 19, 2025, 18:35 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission told a US appeals court that it should affirm an order that denied an injunction against an administrative proceeding against Express Scripts and other pharmacy benefit managers because they aren't likely to succeed on the merits. “Plaintiffs assert that they do not need to show concrete harm because they are suing to enjoin the FTC before it can issue a decision. Plaintiffs do not explain why they should be entitled to an injunction without a showing of harm when—they appear to concede—they could not overturn a final FTC decision based on the exact same argument,” it said. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections